FDA Clears the First Cholesterol Pill in a Class That Was Injection-Only

The FDA approved Lipfendra, the first oral PCSK9 inhibitor, a class previously available only as an injection, with trials showing near-60% LDL reduction.

The US FDA has approved Lipfendra (enlicitide), a once-daily cholesterol pill from Merck. It is the first oral drug in the PCSK9-inhibitor class, which until now has been given only by injection. The drug blocks the PCSK9 protein tied to higher cholesterol and cardiovascular risk, and Merck says it can be added on top of statins.

Two late-stage trials showed the pill lowered LDL in patients with hypercholesterolemia by an average of nearly 60%, according to company-cited results. The trials also indicated it does not carry the same allergy risk as injectable PCSK9 drugs. About a quarter of people with cholesterol issues have hypercholesterolemia, and Merck says 70% of patients on existing therapies still fail to meet guideline targets.

The abundance angle is form factor. An effective daily pill removes the barriers that come with injectable therapy — clinic visits, refrigeration, and injection reluctance — which tend to keep people from starting or staying on treatment. If a pill is easier to prescribe and take, more of the large undertreated population can reach their targets. An RBC analyst estimated 70% or more of eligible high-risk cardiovascular patients remain undertreated.

What to watch is price and rollout, neither of which has been announced — the accessibility gain depends heavily on what the drug costs. And the honest caveats: the efficacy figures come from Merck-cited trials rather than independent review, and the claims about undertreatment and market size come from the company and an analyst, not neutral sources.

Source: New Atlas